Compare WNEB & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WNEB | SGHT |
|---|---|---|
| Founded | 1853 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.3M | 282.9M |
| IPO Year | 2001 | 2021 |
| Metric | WNEB | SGHT |
|---|---|---|
| Price | $12.33 | $3.67 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $12.50 | $9.08 |
| AVG Volume (30 Days) | 64.8K | ★ 361.1K |
| Earning Date | 04-21-2026 | 03-04-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | ★ 33.93 | 28.16 |
| EPS | ★ 0.75 | N/A |
| Revenue | $44,000.00 | ★ $77,363,000.00 |
| Revenue This Year | N/A | $13.54 |
| Revenue Next Year | $5.61 | $14.53 |
| P/E Ratio | $16.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.63 | $2.03 |
| 52 Week High | $14.52 | $9.24 |
| Indicator | WNEB | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 34.39 | 32.11 |
| Support Level | $12.07 | $3.26 |
| Resistance Level | $12.68 | $3.76 |
| Average True Range (ATR) | 0.42 | 0.34 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 21.60 | 4.94 |
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.